Telomir Pharmaceuticals Files 8-K Report
Ticker: TELO · Form: 8-K · Filed: Feb 25, 2025 · CIK: 1971532
Sentiment: neutral
Topics: sec-filing, corporate-info
TL;DR
Telomir Pharma filed a routine 8-K, confirming their Miami HQ and Florida incorporation.
AI Summary
On February 25, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company is incorporated in Florida and its principal executive offices are located in Miami, Florida. The report does not detail specific events but is a standard current report filing.
Why It Matters
This filing serves as a notification to the SEC and investors about the company's ongoing compliance and reporting status. It confirms the company's basic corporate information and location.
Risk Assessment
Risk Level: low — This is a standard procedural filing with no new material information or significant financial events disclosed.
Key Numbers
- 001-41952 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-2606031 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- Florida (location) — State of Incorporation
- Miami (location) — Principal Executive Offices City
- February 25, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating it's a notification of significant events or changes.
When was this report filed?
The report was filed on February 25, 2025.
Where is Telomir Pharmaceuticals, Inc. headquartered?
The company's principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida.
In which state is Telomir Pharmaceuticals, Inc. incorporated?
Telomir Pharmaceuticals, Inc. is incorporated in Florida.
What is the company's SEC file number?
The SEC file number for Telomir Pharmaceuticals, Inc. is 001-41952.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 25, 2025 regarding Telomir Pharmaceuticals, Inc. (TELO).